Gilead and Merck Experience Mixed Results in Recent Trials
In the latest biotech updates, AstraZeneca introduces a GLP-1 pill, while GSK makes headlines with a significant cancer startup acquisition worth $10.6 billion.
Editorial Staff
1 min read
Updated 2 days ago
Gilead and Merck have recently reported contrasting outcomes from their latest clinical trials, highlighting the unpredictable nature of drug development.
In related news, AstraZeneca has launched a new GLP-1 pill, which could impact the diabetes treatment landscape.
Additionally, GSK has made a substantial move by acquiring a cancer startup for $10.6 billion, signaling its commitment to expanding its oncology portfolio.